The clinical trials program of anti-tumor drugs was started by the National Cancer Institute in 1955. In the past 15 years, this national network has collected a large body of data on all of the recognized anti-tumor drugs as well as upon new, experimentally promising agents. While the most important of these studies have been published, there has remained a wealth of data not generally available to the scientific community. Drs. Carter and Livingston have not only succeeded in organ z ng this large corpus, they have in addition analyzed and interpreted the clinical data in a way that will be...